Patents by Inventor David Robert John Readett

David Robert John Readett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CTLA-4 AND CPG-MOTIF-CONTAINING SYNTHETIC OLIGODEOXYNUCLEOTIDE COMBINATION THERAPY FOR CANCER TREATMENT
    Publication number: 20120003179
    Abstract: The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e., CpG ODN PF3512676, for treatment of cancer. The invention relates to administering a combination of an anti-CTLA-4 antibody and CpG ODN PF3512676 as neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g., at any stage of the cancer).
    Type: Application
    Filed: June 24, 2011
    Publication date: January 5, 2012
    Applicants: Coley Pharmaceutical Group, Inc., PFIZER INC
    Inventors: David Robert John READETT, Jarl Ulf Birger Jungnelius, Jesus Gomez-Navarro, Douglas Hanson, Arthur M. Krieg
  • Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
    Publication number: 20090117132
    Abstract: The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e, CpG ODN PF3512676, for treatment of cancer. The invention relates to administering a combination of an anti-CTLA-4 antibody and CpG ODN PF3512676 as neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g, at any stage of the cancer).
    Type: Application
    Filed: June 30, 2006
    Publication date: May 7, 2009
    Applicants: Pfizer, Inc., Coley Pharmaceutical Group, Inc.
    Inventors: David Robert John Readett, Jarl Ulf Birger Jungnelius, Jesus Gomez-Navarro, Douglas Hanson, Arthur M. Krieg
  • COMBINATIONS AND METHODS OF USING AN IMMUNOMODULATORY OLIGODEOXYNUCLEOTIDE
    Publication number: 20090082295
    Abstract: The present invention relates to combination therapies for the treatment of cancer. The combination of agents include oligonucleotides and one or more chemotherapeutic agents.
    Type: Application
    Filed: November 13, 2006
    Publication date: March 26, 2009
    Applicant: PFIZER INC.
    Inventors: Jarl Ulf Birger Jungnelius, David Robert John Readett, Louis J. Denis